We report the case of a 64-year-old ex-smoker with metastatic poorly differentiated squamous cell carcinoma (SCC) of the lung and an epidermal growth factor receptor (EGFR) mutation in exon 21 (p.L858R) who achieved prolonged clinical benefit from treatment with an EGFR tyrosine kinase inhibitor (TKI). The initial diagnosis of SCC of the lung obtained by bronchoscopic biopsy was based on immunohistochemical staining only with positivity for cytokeratin (CK) 5/6 and p63 because morphological diagnosis was not possible. Patients with non-small cell lung cancer (NSCLC), not otherwise specified (NOS) favouring SCC are usually not tested for the presence of EGFR mutations, and therefore may not receive EGFR TKI therapy. A bronchoscopic rebiopsy showed small nests of undifferentiated tumour cells with weak immunoreactivity of some tumour cells for CK5/6, p63 and no positivity of some tumour cells for thyroid transcription factor-1. These findings suggested a mixed squamous/glandular immunophenotype that has been missed at the initial biopsy. Our clinical case illustrates the problem of tumour heterogeneity encountered in small bronchoscopic biopsies and the difficulties of evaluating the histological subtype in poorly differentiated carcinomas. Initial bronchoscopy should be performed by an experienced pulmonologist who attempts to obtain sufficient material from different areas of the tumour. In the era of targeted therapy, a remote smoking history in a patient with NOS favouring SCC should also
Thomas Kluckert lead to EGFR mutation testing to allow highly effective therapy to be offered to mutationpositive patients.
Case Description
An otherwise healthy 64-year-old Caucasian man presented with worsening right inguinal pain since 3 months. He had a 30 pack-years smoking history until 25 years ago. A computed tomography scan showed a 7 × 7.5-cm mass infiltrating the right psoas muscle, a right-sided hilar lung lesion, enlarged ipsilateral mediastinal lymph nodes and a 4.5 × 3-cm adrenal mass. A bronchoscopic biopsy confirmed a poorly differentiated carcinoma, positive for p63, CK5/6 and negative for TTF-1 (thyroid transcription factor-1) on immunohistochemical staining ( fig. 1a-d) . The pathology report stated a poorly differentiated squamous cell carcinoma (SCC) of the lung, and systemic therapy was initiated. Unfortunately, the patient progressed after two cycles of first-line chemotherapy with carboplatin and paclitaxel and subsequently received palliative radiotherapy with 50 Gy for the psoas metastasis and the primary tumour. In addition, an epidermal growth factor receptor (EGFR) mutation analysis from the initial tumour material revealed an activating point mutation in exon 21 (p.L858R). The EGFR tyrosine kinase inhibitor (TKI) erlotinib was started resulting in a partial remission after 8 weeks of therapy, and the patient became asymptomatic and unrestricted in his physical activity ( fig. 2 ). Twenty-two months later, he developed multifocal progression with lung and liver metastases. A bronchoscopic rebiopsy showed small nests of undifferentiated tumour cells with weak immunoreactivity of some tumour cells for p63, CK5/6 and also positivity of some tumour cells for TTF-1, suggesting a mixed squamous/glandular immunophenotype ( fig. 3a-d ). Third-line chemotherapy remained unsuccessful, and the patient died 33 months after initial diagnosis.
Discussion
Median survival rates in chemotherapy-refractory, unselected patients are less than 6 months with either erlotinib or chemotherapy [1] . Second-line EGFR TKIs are offered to fewer than 25% of these patients [1] . If EGFR mutation testing had not been performed, our patient would have likely missed the opportunity of having a symptom-free period of almost 2 years with EGFR TKI therapy. Several factors are known to be associated with the presence of an activating EGFR mutation: female gender, non-smoking history, Asian ethnicity and adenocarcinoma. The incidence of EGFR mutations in SCC is rare, particularly in Caucasian patients (<5%) [2] . A study on 95 resected pure SCC patients suggested that EGFR mutations are usually absent [3] . According to the recent ESMO guidelines, molecular testing is recommended in never or former light smokers (<15 pack-years) with SCC of the lung [4] . Since none of these clinico-pathological criteria applied to the patient, the EGFR mutation has not been determined at initial diagnosis.
The pathological diagnosis of lung tumours is based on the 2004 WHO criteria [5] . Of note, this classification was established on resected tumour material, which is available in only 30% of non-small cell lung cancer (NSCLC) patients. Our case illustrates several pitfalls in determining the histological subtype. The morphological diagnosis of SCC was not possible due to the lack of keratinisation and intercellular bridges. Therefore, immunohistologic staining to assist in the identification of the histological subtype is recommended [6] . The most important antibodies include TTF-1, CK5/6, and p63. Although a high correlation with SCC and positive immunoreactivity for CK5/6 and p63 have been reported, the correct wording of the initial pathology report should have been NSCLC, not otherwise specified (NOS) favouring SCC according to the immunohistologic markers [6, 7] . This classification has recently been proposed for small biopsies/cytology samples to clarify whether diagnosis was based on morphology or special stains [6] . However, only patients with adenocarcinoma (i.e. morphological diagnosis), NSCLC NOS favouring adenocarcinoma (i.e. special stains) and patients with NSCLC NOS are generally considered for EGFR mutation testing in clinical practice. In patients with a clear morphological diagnosis of SCC or NSCLC NOS favouring SCC, routine testing is not recommended [6] . It is very important to keep in mind that all current clinical trials justifying the importance of the distinction between histologic types are based on light microscopy alone, and our knowledge on the incidence of activating EGFR mutations in patients with true NSCLC NOS and NSCLC NOS favouring adenocarcinoma or SCC according to immunohistochemical marker profile is limited [8] [9] [10] [11] . Our case raises the question whether EGFR mutation testing should be advocated in all patients with a bioptic diagnosis of NSCLC who morphologically lack glandular or squamous differentiation (i.e. NOS), independent of the results of specific stains, particularly in patients with clinical characteristics commonly associated with an EGFR mutation such as a remote smoking history in our patient.
Rebiopsy after progression on EGFR TKI therapy immunohistochemically suggested the presence of a mixed adenosquamous subtype, a condition described in approximately 5% of NSCLC on resected tumour tissue [6] . Although bronchoscopic biopsies have the advantage of being minimally invasive compared to surgical biopsies, they carry the risk of containing a variable amount of tumour tissue that may not be representative for the tumour burden as a whole, and a mixed adenosquamous subtype may be overlooked (sampling error).
Our case illustrates the importance of a multidisciplinary approach and close collaboration among pulmonologists, pathologists and oncologists in treating patients with stage IV NSCLC. Due to tumour heterogeneity, every effort should be made by the experienced pulmonologist to obtain sufficient material from different areas of the tumour. In our opinion, a remote smoking history in a patient with NSCLC NOS favouring SCC should also lead to EGFR mutation testing to allow highly effective therapy to be offered to mutationpositive patients. Genetic analyses such as high-throughput gene profiling and miRNA studies hold promise in supporting classification of lung cancer subtypes and have the potential to assist the classical morphologic and immunohistochemical diagnosis in the near future.
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